Journal article

Is It Cost-Effective To Increase Aspirin Use in Outpatient Settings for Primary or Secondary Prevention? Simulation Data from the REACH Registry Australian Cohort

Zanfina Ademi, Danny Liew, Bruce Hollingsworth, Ph Gabriel Steg, Deepak L Bhatt, Christopher M Reid

CARDIOVASCULAR THERAPEUTICS | WILEY-HINDAWI | Published : 2013

Abstract

AIMS: To describe aspirin use in primary and secondary prevention and to determine the incremental costs-effectiveness ratio (ICER) per life year gain (LYG) of aspirin use among subjects with, or at high risk of atherothrombotic disease. DESIGN AND SUBJECTS: To project the cost-effectiveness of aspirin over 5 years of follow-up, a Markov state transition model was developed with yearly cycles and the following health states: "Alive" (post-CAD) and "Dead." The model compared current coverage observed among 2361 subjects using the prospective Australian subset of Reduction of Atherothrombosis for continued Health (REACH) registry, and hypothetical situation whereby all subjects assumed to be t..

View full abstract

Grants

Awarded by Australian Research Council (ARC)


Funding Acknowledgements

This work was supported by Monash University. In addition, this work was supported in part by the Australian Research Council (ARC) Linkage Project LP077532. The global REACH Registry is sponsored by sanofi-aventis, Bristol-Myers Squibb and the Waksman Foundation (Tokyo, Japan), and is endorsed by the World Heart Federation. The REACH Registry enforces a no-ghost-writing policy. A complete list of the REACH Registry Investigators appears in JAMA. 2006; 295(2):180-189.Zanfina Ademi and Bruce Hollingsworth declare no conflict of interest. Christopher Reid has received research funding and honoraria from sanofi-aventis, MSD, Servier and AstraZeneca. Danny Liew has received research grants and honoraria from sanofi-aventis and Pfizer (sponsor of atorvastatin). Ph Gabriel Steg has the following disclosures: Research Grant (to institution): Servier (2009-2014), Consulting/advisory board: Astellas, C. Bayer, Boehringer-Ingelheim, BMS, Daiichi-Sankyo-Lilly, GSK, Medtronic, MSD, Otsuka, Pfizer, Roche, sanofi-aventis, Servier, The Medicines Company. Stockholding: Aterovax. Deepak L. Bhatt has received research grants from sanofi-aventis and Bristol-Myers Squibb who have funded the REACH Registry. He has also received institutional research support from AstraZeneca, Eisai, and The Medicines Company.